Point of care detection and diagnosis of oral cancer using a low cost imaging module enabled by AI
Active Cooperative Agreement Awarded Last action
- Award ID
- U01CA291666
- Recipient
-
GE Medical Systems Information Technologies, Inc. UEI G2JTZ3UQV9M3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $990,038
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 44% complete
- Place of performance
- Schenectady, NY 12309, USA
Award details come from USAspending.gov.
Description
- Abstract
- The overall vision of the proposed project is to to develop and deploy an affordable automated point-of-care (POC) telecytology platform for oral cancer screening that will reliably establish a diagnosis of oral cancer in the community setting and establish an immediate referral care pathway. Oral cancer is a significant public health problem in india; 77,000 new cases and 52,000 deaths are reported annually, which is approximately one-fourth of global incidences. Approximately 70% of cases present at an advanced stage, when the probability of cure is very low, and a five-year survival rate is around 20%. IT has been estimated that early diagnosis, with timely and proper treatment, could improve the survival rate up to 90%. The current 'gold standard' of oral cancer screening is visual inspection of the mouth by trained individuals, followed by biopsy of suspicious lesions. However, in india there is a delay of nine months from the onset of symptoms to diagnosis. Of this, seven months are attributed to the delays within the medical pathway the majority of the population lives in a rural environment, where access to pathology services and expertise is very limited. Without definitive proof of cancer, patients are not eligible for state-run insurance programs for treatment. Our proposed approach comprises a portable system for scanning brush biopsy cytology slides with cloud connectivity for transmission of images to pathologists and/or automated diagnosis via a validated algorithm for identification of atypical cells. After standard visual triaging of patients during routine screening, those identified with higher risk lesions will immediately be directed to undergo brush biopsies on the same day. Samples will be placed on a glass slide, stained with routine toluidine blue (average time is
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $211,128 | |
| Amendment | $300,334 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $478,576 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Indian Institute Of Science | $226,080 |
Quick answers
Who received award U01CA291666?
U01CA291666 was awarded to GE Medical Systems Information Technologies, Inc. by National Cancer Institute (National Institutes of Health) on September 13, 2024.
How much is award U01CA291666 worth?
$990,038 has been obligated on U01CA291666.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award